News & Blog

News & Blog

  • Reset
News | Jul 23 2024

Job Opening – Accounting Specialist

FARA News
News | Jul 16 2024

FARA Advocates for Effective Inclusion of Children Early in Clinical Trials at Pediatric Inclusion Roundtable

Advocacy | FARA News
News | Jul 16 2024

2023 Donor Impact Report

FARA News
News | Jul 15 2024

LEXEO Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Industry News
News | Jun 18 2024

C-Path Partners with FARA to Fortify RDCA-DAP and Further Accelerate Drug Development with new Friedreich’s Ataxia Data

Partner News
News | May 30 2024

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia

Industry News
News | May 20 2024

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open l...

Industry News
News | May 17 2024

The Oxford-Harrington Rare Disease Centre Announces Newly Funded Grant Award Programmes to Develop New Therapies for Friedreich’s Ataxia

Partner News
News | May 8 2024

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Industry News
News | Apr 25 2024

Astellas shares that US FDA cleared their IND with Fast Track designation for Phase 1 trial of their investigational gene therapy for the treatment of cardiomyopathy in FA

In a communication to FARA and the FA Community, Astellas shared that the US FDA has cleared their Investigational New Drug with a fast ...

Industry News
News | Apr 22 2024

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Industry News
News | Apr 17 2024

Muscular Dystrophy Association and Friedreich’s Ataxia Research Alliance Announce Collaborative Research Grant Using Novel Gene Editing Technology to Address Root Cause of Friedreich’s Ataxia Disease

Partner News